Leela Barham takes a look behind the schemes for patient access in England and puts the case for a review to bring them up to date, in the light of changes since they began in 2009.
NICE says it can approve BioMarin's ultra-rare drug treatment Vimizim, but has proposed real-world data collection and a price cap to overcome doubts about the drug's value, reports Andrew McCo
NICE is to establish a new Office for Market Access to help life sciences companies prepare for its cost effectiveness appraisals and improve their chances of gaining a 'yes'.